smc evaluation project the view from industry n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
SMC Evaluation Project The View From Industry PowerPoint Presentation
Download Presentation
SMC Evaluation Project The View From Industry

Loading in 2 Seconds...

play fullscreen
1 / 18

SMC Evaluation Project The View From Industry - PowerPoint PPT Presentation


  • 70 Views
  • Uploaded on

SMC Evaluation Project The View From Industry. Martin Coombes Government Affairs Manager, AstraZeneca ABPI Representative SMC Evaluation Reference Group. “The Pharmaceutical Industry is recognised as a key partner by SMC and have supported the development of a robust and

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'SMC Evaluation Project The View From Industry' - sienna


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
smc evaluation project the view from industry

SMC Evaluation ProjectThe View From Industry

Martin Coombes

Government Affairs Manager, AstraZeneca

ABPI Representative SMC Evaluation Reference Group

slide2

“The Pharmaceutical Industry is recognised as a key partner by

SMC and have supported the development of a robust and

transparent decision-making process.”

slide3

Life Science Message

Scottish Medicines Consortium Work

smc evaluation project

SMC Evaluation Project

Management Group: Paul Catchpole

Reference Group: Martin Coombes, Jim Swift Andrew McGuigan

ABPI Scotland: Andy Powrie-Smith

SMC User Group Forum

smc evaluation project1
SMC Evaluation Project
  • Stakeholder engagement
  • Medicines utilisation
    • Not recommended
    • Accepted for use/restricted use
    • SMC advice on unique treatment
  • Evaluation of Budget Impact
stakeholder engagement
Stakeholder Engagement
  • Evolving process
  • Industry seen as partner
    • Continue to increase communication
  • SMC process well recognised, timely, straightforward
  • Consistent advice, but varying NHS Board processes and application, which would benefit from greater transparency
  • Reduce duplication – NICE/AWMSG
  • More proactive patient involvement
medicines utilisation
Medicines Utilisation
  • Not recommended
medicines utilisation1
Medicines Utilisation
  • Not recommended
    • 10 medicines remained not recommended 0.1% of the primary care spend 2005/6
    • Not added to formulary
    • No means No
medicines utilisation2
Medicines Utilisation
  • Not recommended
    • Delay of SMC advice
    • Limited use relative to alternative treatments
    • No alternative licensed products
    • Influence of pharmaceutical industry marketing strategy
    • Variation in advice issued by national bodies
    • Lack of engagement of relevant clinical experts in early stages of SMC
medicines utilisation4
Medicines Utilisation
  • Accepted/Restricted Use
    • Data limitations
    • ‘Where alternative treatments already exist, implementation of advice is subject to local NHS Board decision making’
    • Acceptable variation?
    • Yes means Maybe
unique treatment
Unique Treatment
  • Etanercept for psoriatic arthritis
    • HDL (2003) 60
    • No clean and relevant dataset
    • No single Scottish centre to collate data
    • Issues around local organisation structure
budget impact
Budget Impact
  • Variable
    • Actual vs Budget Impact
      • From +£3.2m to -£11.9m
    • Multiple issues
      • Derivation unclear, Trial drop-out rates, ‘Restricted Use’, lack of uptake
    • Compare actual uptake vs BI
      • Between NHS Boards
      • Other countries

Forward Look SMC Budget Impact

key conclusions
Key Conclusions
  • Evolving and improving
  • Engagement
    • More Pt group contact & Industry communication
    • Need greater understanding of local NHS Board processes To provide consistency, transparency and accessibility
  • Medicines Utilisation
    • Data? Variation in uptake?
    • When does yes mean yes?
    • Regular monitoring of uptake (compare with other countries)
  • Budget Impact
    • Robust
    • Actual vs Budget Impact